Tirzepatide for weight loss: what SURMOUNT-1 found

Tirzepatide had already been approved as Mounjaro for type 2 diabetes when Eli Lilly ran the trial that would decide whether it worked as a weight-loss drug on its own. SURMOUNT-1 was built to answer exactly that, in people who did not have diabetes at all.

It was a phase 3, double-blind, placebo-controlled trial. Researchers randomized 2,539 adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related complication, in a 1:1:1:1 ratio to once-weekly subcutaneous tirzepatide at 5mg, 10mg, or 15mg, or to placebo, for 72 weeks. That included a 20-week dose-escalation period before participants reached their assigned maintenance dose.

Diabetes was an exclusion criterion, not an afterthought. At baseline, mean body weight was 104.8kg and mean BMI was 38.0; 94.5% of participants had a BMI of 30 or above. This is a different population from the SURPASS trials that supported Mounjaro's original diabetes approval.

The two co-primary endpoints were percentage change in body weight from baseline to week 72, and the proportion of participants achieving a weight reduction of 5% or more. Both were analyzed under a treatment-regimen estimand — meaning outcomes were counted for everyone regardless of whether they stayed on their assigned dose the whole time.

Nearly everyone on tirzepatide lost a meaningful amount of weight. Across the three doses, 85%, 89%, and 91% of participants lost at least 5% of their body weight, compared with 35% on placebo (P<0.001 for every comparison). The gap wasn't marginal — it was the difference between "most people respond" and "most people don't."

The dose-response held all the way up. Half of the 10mg group and 57% of the 15mg group lost a fifth or more of their body weight, versus 3% on placebo. Each step up in dose bought more average weight loss, which is the basis for titrating to the highest tolerated dose rather than stopping at the first one that works.

Improvements were also seen across prespecified cardiometabolic measures. The most common adverse events were gastrointestinal — nausea, diarrhea, constipation — mostly mild to moderate and concentrated during dose escalation. Treatment discontinuation because of adverse events occurred in 4.3%, 7.1%, and 6.2% of the 5mg, 10mg, and 15mg groups, versus 2.6% on placebo.

This trial is the reason Zepbound exists. SURMOUNT-1 enrolled people without diabetes, and its results were the basis for the FDA approving tirzepatide under a second brand name, Zepbound, for chronic weight management in late 2023 — the same molecule as Mounjaro, sold under a different name for a different approved use.

The dose you land on matters more than it sounds. Because weight loss scaled with dose across all three arms, staying at a low maintenance dose because titration felt uncomfortable trades away a meaningful chunk of the average effect seen in this trial.

Dose escalation is where the friction is. GI side effects clustered in the 20-week ramp-up, and that's also when 4-7% of participants stopped altogether. Tracking symptoms against dose changes gives a prescriber something concrete to act on before a bad week becomes a reason to quit.

An average hides a range. Roughly one in ten people on the 15mg dose did not reach even a 5% loss. A 20.9% average is a population result, not a guarantee for any one person starting the same regimen.

This article summarizes a published randomized controlled trial for general education. It is not medical advice. Individual results vary, and any decision about starting, switching, adjusting, or stopping any GLP-1 or GIP/GLP-1 medication should be made with a prescriber.